) -- Biotech investors take note: On Weds. May 18, the American Society of Clinical Oncology (ASCO) will be posting online the full content of cancer drug research abstracts to be presented next month at its closely watched annual meeting in Chicago.


ASCO research abstracts

will be posted on the medical society's web site starting at 6 p.m. EDT -- free for everyone to browse and download. The ASCO annual meeting -- the most important cancer drug research meeting every year -- runs June 3-7.


traders start focusing on "ASCO stocks" early in the year

, well before the release of research abstracts.

A research abstract is simply a summary of clinical data to be presented at a medical conference. The abstract typically includes a brief description of the clinical study, the types of patients enrolled and sometimes, a brief summary of the study results, including efficacy and safety data.

Research abstracts can be flinty on the important details investors want to know. Think of a research abstract as a placeholder a company uses to reserve a spot at a medical meeting. A cancer research meeting like ASCO is a very hot ticket, so companies vie for presentation slots well in advance. Often, that means the cancer drug data companies want to present isn't ready or fully analyzed yet. ASCO abstracts, therefore, often summarize the study but put off disclosing the important details (like if the drug being studied works and is safe) until the actual data presentation at the meeting.

To make it easier for investors to search ASCO's annual meeting web site next Wednesday, I put together a list of abstracts most interesting to Wall Street, arranged alphabetically by drug sponsor.

Ariad Pharmaceuticals




(MRK) - Get Merck & Co., Inc. (MRK) Report

Abstract No. 10005

Abstract title: Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).


(ARQL) - Get ArQule, Inc. Report

Abstract No. TPS217

Abstract title: A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

Abstract No. LBA5 (plenary session)

Abstract title: Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

Cell Therapeutics

(CTIC) - Get CTI BioPharma Corp. Report

Abstract No. 6517

Abstract title: Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML.


(EXEL) - Get Exelixis, Inc. Report

Abstract No. (Not listed)

Abstract title: Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

Abstract No. 4516

Abstract title: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Johnson & Johnson

(JNJ) - Get Johnson & Johnson (JNJ) Report

Abstract No. 4500

Abstract title: Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study.

Abstract No.: 4520

Abstract title: Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.


(INCY) - Get Incyte Corporation (INCY) Report

Abstract No. 6500

Abstract title: Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).



Abstract No. 4501

Abstract title: MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report.

Nektar Therapeutics

(NKTR) - Get Nektar Therapeutics Report

Abstract No. 1034

Abstract title: Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).

Abstract No. 5047

Abstract title: The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).



Abstract No: LBA8526

Abstract title: A phase III study of receptor-targeted tilmanocept versus blue dye in evaluation of SLNs in breast cancer and melanoma.



Abstract No. 4502

Abtstract title: An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model.

Onyx Pharmaceuticals


Abstract No. 8025

Abstract title: Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).

TheStreet Recommends

Abstract No. 8026

Abstract title: The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naïve relapsed or refractory multiple myeloma (MM): Updated results from the PX-171 004 study.

Abstract No. 8027

Abstract title: PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.


(PFE) - Get Pfizer Inc. Report

Abstract No.: 4503

Abstract title: Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.



Abstract No. 6508

Abstract title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocyticlymphoma (CLL/SLL): Interim results of a phase Ib/II study.

Regeneron Pharmaceuticals

(REGN) - Get Regeneron Pharmaceuticals, Inc. Report

Abstract No. 5017

Abstract title: Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.


Abstract No. LB4

Abstract title: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E-BRAF-mutated melanoma.Sun. Junr 5, 3:15 pm (Plenary session)




(IMGN) - Get ImmunoGen, Inc. Report

Abstract No. TPS102

Abstract title: MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

Abstract No. TPS116

Abstract title: EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.




(CRIS) - Get Curis, Inc. Report

Abstract No. TPS173

Abstract title: A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376).


(SNY) - Get Sanofi Sponsored ADR Report

Abstract No. 1007

Abstract title: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

Synta Pharmaceuticals


Abstract No. 7500

Abstract Title: An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).



Abstract No: 8572

Abstract title: Association of response and survival in Allovectin melanoma trials.

YMI Biosciences


Abstract No. 6514

Abstract title: Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.

Ziopharm Oncology

(ZIOP) - Get ZIOPHARM Oncology, Inc. Report

(Note: These are



Abstract No. 2540

Abstract title: Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand.

Sources: BioMedTracker; TheStreet research; analyst, company reports.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.